Brief: Actinium Provides Update On Iomab-B Sierra Trial And Expected Topline Results From Ad HOC Analysis In 2020
16/04/2020 12:50
April 16 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PROVIDES UPDATE ON IOMAB-B SIERRA TRIAL AND
EXPECTED
TOPLINE RESULTS FROM AD HOC ANALYSIS IN 2020
* ACTINIUM -SINGLE AD HOC INTERIM ANALYSIS FOR SIERRA TRIAL
TO BE
EXERCISED AT CO'S DISCRETION IN Q2,MAKING TOPLINE DATA RESULTS
AVAILABLE IN Q4
* ACTINIUM PHARMACEUTICALS - SIERRA TRIAL IS APPROACHING
UPPER
BOUND OF RANGE WITHIN WHICH COMPANY MAY EXERCISE AN AD HOC
ANALYSIS OF TOPLINE RESULTS
Source text for Eikon: ID:nPn2MmnY0a
Further company coverage: ATNM.A
(Reuters.Briefs@thomsonreuters.com)
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities